Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
A phase 2 trial of Cobimetinib in melanoma, run by Hanmi Pharmaceutical Company Limited, now recruiting.
Overview
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma is a phase 2 interventional study registered as NCT07449754 by Hanmi Pharmaceutical Company Limited, with 45 participants planned, started 2026-02-12 and due to reach its primary completion in 2029-09. Interventions recorded: Belvarafenib, Cobimetinib. Conditions listed: Advanced or Metastatic Melanoma. No results are recorded here; the registry entry is the source.
Setting
A Phase 2, Multicenter, Single-Arm Study of Belvarafenib (HM95573) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Phase
Phase 2
Sponsor
Hanmi Pharmaceutical Company Limited
Registry
Enrolled
45
Similar pages
not linked directly; found by shared links- PersonGrant McArthur
Shares Cobimetinib, Melanoma.
- PathwayMelanoma (KEGG map)
Shares Cobimetinib, Melanoma.
- TreatmentVemurafenib
Shares Cobimetinib, Melanoma.
- CancerErdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms
Shares Cobimetinib, Melanoma.